<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884049</url>
  </required_header>
  <id_info>
    <org_study_id>METC 2018-081</org_study_id>
    <secondary_id>2018-081</secondary_id>
    <nct_id>NCT03884049</nct_id>
  </id_info>
  <brief_title>Neovascularization Embolisation for Knee Osteoarthritis.(NEO)</brief_title>
  <acronym>NEO</acronym>
  <official_title>Novel Transcatheter Arterial Embolization for Treatment of Knee Osteoarthritis: a Randomized Sham-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Cook Europe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Coolsingel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double blind randomized sham controlled study the investigators want to establish the&#xD;
      efficacy of transcatheter arterial embolization of neovessels for patients with symptomatic&#xD;
      mild to moderate knee osteoarthritis after 4 months compared to a sham-embolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Transcatheter arterial embolization has recently been proposed as an efficacious therapy for&#xD;
      therapy-resistant osteoarthritis of the knee, providing substantial pain reduction at&#xD;
      short-term as well as long-term follow-up up till 4 years.&#xD;
&#xD;
      A potential working mechanism of treatment effect is that the normalization of the amount of&#xD;
      blood vessels and blood flow achieved by embolization reduces inflammation, resulting in pain&#xD;
      reduction&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The main objective is to assess whether transcatheter arterial embolization of neovessels in&#xD;
      patients with symptomatic knee OA results in significant pain reduction after 4 months&#xD;
      compared to sham treatment.&#xD;
&#xD;
      The investigators hypothesize that novel transcatheter arterial embolization of neovessels is&#xD;
      a feasible, effective, and safe treatment for patients with symptomatic radiographic knee OA,&#xD;
      resulting in significant improvement of pain symptoms in a period of 4 months follow-up&#xD;
      compared to sham embolization.&#xD;
&#xD;
      Secondary objectives are&#xD;
&#xD;
        1. to assess whether reduction of neovessels is related to pain relief,&#xD;
&#xD;
        2. to explore whether decrease of inflammation is a mediating factor between neovessel&#xD;
           reduction and pain relief,&#xD;
&#xD;
        3. to assess whether transcatheter arterial embolization reduction of neovessels decreases&#xD;
           peripheral and central pain sensitization and&#xD;
&#xD;
        4. to assess whether transcatheter arterial embolization improve the outcome at 1, 4, 8 and&#xD;
           12 months compared to placebo of the: ICOAP, painDETECT, EQ-5D-5L questionnaires and NRS&#xD;
           for pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded randomized placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>KOOS pain sub score</measure>
    <time_frame>4 months</time_frame>
    <description>KOOS pain sub score after 4 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total KOOS</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>Total KOOS result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>painDETECT questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>painDETECT questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICOAP questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>ICOAP questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score 0-10 Numerical Rating Scale (NRS)</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults.&#xD;
The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. &quot;no pain&quot;) to '10' representing the other pain extreme (e.g. &quot;pain as bad as you can imagine&quot; or &quot;worst pain imaginable&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L questionnaire</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>EQ-5D-5L questionnaire results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain threshold testing</measure>
    <time_frame>1,4,8,12 month(s)</time_frame>
    <description>Pressure pain threshold testing results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee MRI</measure>
    <time_frame>1 and 4 month(s)</time_frame>
    <description>Knee MRI scan results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Embolization group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group undergoes transcatheter arterial embolization of neovessels around the knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Embolization Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group undergoes sham embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization</intervention_name>
    <description>transcatheter arterial embolization of neovessels around the knee</description>
    <arm_group_label>Embolization group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham embolization</intervention_name>
    <description>Sham transcatheter arterial embolization of neovessels in the knee</description>
    <arm_group_label>Sham Embolization Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age.≥18 years&#xD;
&#xD;
          -  Knee pain for a duration of ≥ 6 months&#xD;
&#xD;
          -  Knee pain (numeric rating scale ≥4 - ≤8) on at least half of the days in the preceding&#xD;
             month at time of inclusion.&#xD;
&#xD;
          -  There is insufficient response of conservative treatment for at least 6 months&#xD;
&#xD;
          -  Radiographic knee osteoarthritis (radiographic Kellgren and Lawrence grade 1-3)&#xD;
&#xD;
        Exlusion criteria:&#xD;
&#xD;
          -  Contra-indications for MRI (e.g. metallic foreign bodies, etc.)&#xD;
&#xD;
          -  Contra-indications for angiography&#xD;
&#xD;
          -  Renal insufficiency, checked with blood sample test (GFR &lt; 30 ml/min/1, 73 m2);&#xD;
&#xD;
          -  Known allergy to contrast agents;&#xD;
&#xD;
          -  Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane,&#xD;
             polyphosphazene&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Intermittent claudication of affected limb&#xD;
&#xD;
          -  Intra articular injections in the ipsilateral knee less than 6 months ago&#xD;
&#xD;
          -  On the waiting list for joint replacement surgery&#xD;
&#xD;
          -  Amitriptyline usage.&#xD;
&#xD;
          -  Patient has known allergies to barium sulfate, 3-aminopropyltrialkoxysilane,&#xD;
             polyphosphazene.&#xD;
&#xD;
          -  Insufficient command of the Dutch or English language.&#xD;
&#xD;
          -  Legally incompetent adults.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Edwin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriaan Moelker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin Oei, MD, PhD</last_name>
    <phone>31 10 7040619</phone>
    <email>e.oei@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tijmen A Zadelhof, PhD student</last_name>
    <phone>31 10 7030420</phone>
    <email>t.vanzadelhoff@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Edwin Oei</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>ranscatheter</keyword>
  <keyword>embolization</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>arterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not as yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

